Gianluca Tomasello

ASST Bergamo Ovest, BG
Treviglio, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 180 publications

Early onset pancreatic Cancer: epidemiology, molecular features, and clinical outcomes.

Early onset pancreatic Cancer: epidemiology, molecular features, and clinical outcomes.

Journal: Cancer treatment reviews

Published: April 14, 2026

Upfront Chemotherapy Versus Immediate Surgery for Operable Pancreatic Cancer: An Umbrella Review of Meta-Analyses.

Upfront Chemotherapy Versus Immediate Surgery for Operable Pancreatic Cancer: An Umbrella Review of Meta-Analyses.

Journal: Cancers

Published: March 21, 2026

Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data From the LOR-HCC (Lombardy Real-World HCC Group).

Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data From the LOR-HCC (Lombardy Real-World HCC Group).

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: January 24, 2026

Viral hepatitis and immunotherapy outcome in advanced hepatocellular carcinoma: A comprehensive umbrella review of 15 meta-analyses.

Viral hepatitis and immunotherapy outcome in advanced hepatocellular carcinoma: A comprehensive umbrella review of 15 meta-analyses.

Journal: Critical reviews in oncology/hematology

Published: January 22, 2026

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.

Journal: Clinical lung cancer

Published: January 11, 2026

Subcutaneous Immunotherapy in Cancer: Where We Are Now, What It Changes, and What to Watch Next.

Subcutaneous Immunotherapy in Cancer: Where We Are Now, What It Changes, and What to Watch Next.

Journal: JCO oncology practice

Published: January 09, 2026

Mol* web molecular graphics engine.

Mol* web molecular graphics engine.

Journal: Protein science : a publication of the Protein Society

Published: November 19, 2025

Advanced cholangiocarcinoma in 2025: Therapeutic sequencing and global implementation.

Advanced cholangiocarcinoma in 2025: Therapeutic sequencing and global implementation.

Journal: Med (New York, N.Y.)

Published: September 19, 2025

A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study.

A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: September 13, 2025

Clinical Evidence for Microbiome-Based Strategies in Cancer Immunotherapy: A State-of-the-Art Review.

Clinical Evidence for Microbiome-Based Strategies in Cancer Immunotherapy: A State-of-the-Art Review.

Journal: Medicina (Kaunas, Lithuania)

Published: August 06, 2025

Prognostic Factors and Survival Outcomes in Resected Biliary Tract Cancers: A Multicenter Retrospective Analysis.

Prognostic Factors and Survival Outcomes in Resected Biliary Tract Cancers: A Multicenter Retrospective Analysis.

Journal: Cancers

Published: June 15, 2025

Immunotherapy-Associated Renal Dysfunction in Metastatic Cancer: An Emerging Challenge in Onco-Nephrology.

Immunotherapy-Associated Renal Dysfunction in Metastatic Cancer: An Emerging Challenge in Onco-Nephrology.

Journal: Cancers

Published: May 22, 2025

Showing 1-12 of 180

Last Updated: 09/26/2026